Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Tarl Prow

Tarl Prow

Deputy Director
Dermatology Research Centre, University of Queensland
Queensland, Australia


Dr. Tarl Prow is the Deputy Director of the Dermatology Research Centre within the School of Medicine and heads a group of 10 researchers focused on nanotechnology and micromedical devices for dermatology. In 2004, Dr. Prow earned his Ph.D. from the University of Texas in the field of Nanomedicine. He then completed his NIH-T32 funded fellowship at The Johns Hopkins Hospital and was faculty there until he relocated to the University of Queensland in Brisbane, Australia in 2007. He is multidisciplinary researcher with internationally recognized expertise in the fields of micro-medical device development, nanodermatology and topical drug delivery. Since joining the University of Queensland, Dr. Prow has published more than 50 peer reviewed manuscripts in top journals with an average impact factor of 6.15. He more than 35 total publications in top ranked journals including Advanced Drug Delivery Reviews, Hepatology, Nucleic Acids Research, Biomaterials, Advanced Functional Materials, Small, Nanomedicine and Journal of Controlled Release. Dr. Prow is an inventor on 6 patents and patent applications in the areas of nano- and micro-medical devices. "Skin cancer diagnosis is moving toward more accurate, non-invasive approaches with in vivo imaging techniques at the forefront. My group has worked with clinicians to develop automated image analysis software to identify lesions suspicious for skin cancer. We have developed a stacked 3D microneedle device, MicrobiopsyTM, for instantaneously capturing small pieces of skin from suspicious lesions for molecular analysis. Finally, we have developed and patented a novel platform for field-directed drug delivery, Foroderm™. Together, these technologies are the first step toward quantum improvements in how skin cancer is detected and treated."

Research Interest